Aurobindo Pharma’s Inspection Results Analyzed
Aurobindo Pharma announced that the U.S. Food and Drug Administration (FDA) finished a check of APL Healthcare’s factory in Palchur, India. This inspection ran from December 8th to December 17th, 2025. The FDA found some minor issues, which led to a report called Form 483, containing five observations.
Key Points
- FDA finished inspecting APL Healthcare’s Palchur, India factory.
- Form 483 issued, with five procedural observations discovered.
- Aurobindo Pharma focuses on medicines and their production.
- Net profit grew 3.8% to Rs 848.45 crore (Q2 FY26).
- Net sales increased 7.7% to Rs 8,236.96 crore (Q2 FY26).
- Stock price rose 0.36% to Rs 1,197.40 on the BSE.
About Aurobindo Pharma
Aurobindo Pharma is a company that makes medicines – specifically, the active ingredients inside pills and tablets, as well as finished medicines. They also offer services related to medicine production. They’re a big player in the global pharmaceutical market.
Financial Performance
Aurobindo Pharma’s recent financial results show a positive trend. Their net profit increased by 3.8% compared to the same period last year. This was driven by a strong rise in their sales, up 7.7%.
Next Steps
Aurobindo Pharma will now respond to the FDA’s findings within the required timeframe, addressing each observation to ensure continued compliance and access to the U.S. market.
“Effective pharmaceutical oversight and rapid response to FDA observations are crucial for sustained market access.”
